Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Professional Diversity Network reported Q3 2026 financial results, showing a 48.2% revenue decline to $0.86 million, primarily due to reduced demand in its TalentAlly and RemoteMore segments. Despite the revenue drop, the company improved its working capital to $0.2 million and launched a new GPU computing initiative through PDN Intelligence, Inc. to enter the AI infrastructure market.
Term
Q3 2026
“Our third quarter results reflect our continued focus on financial discipline, operational efficiency, and strategic business development. We have made meaningful progress in strengthening our working capital position and managing operating expenses while continuing to explore new growth opportunities.”
Bella Gu, Chief Executive Officer and Chief Financial Officer
“The launch of our graphics processing unit (“GPU”) computing initiative through PDN Intelligence, Inc. represents an important step in our strategy to expand into artificial intelligence (“AI”) infrastructure and computing services.”
Bella Gu, Chief Executive Officer and Chief Financial Officer
HeartCore Enterprises reported a significant decline in revenue to $269,852 for the nine months ended September 30, 2026, compared to $1,666,519 in the prior year, resulting in a net loss of $3,792,658. The company underwent a 1-for-20 reverse stock split on April 2, 2026, and is currently managing the disposal of discontinued operations.
Microbot Medical provided a third quarter 2026 operational update highlighting a 44% sequential increase in procedure utilization for its LIBERTY Endovascular Robotic System. The company ended the quarter with $62 million in cash and expanded its commercial footprint to 12 customer accounts and 10 sales territories.
Empery Digital Inc. repurchased 194,625 shares of its common stock during the week ended November 13, 2026, at an average price of $2.09 per share. These transactions were part of an existing $200 million share repurchase program, which now has approximately $49 million in remaining authorization.
Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.
Term
Q3 2026
“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
Virginia National Bankshares Corp reported net income of $6.6 million for the third quarter of 2026, a significant increase from $4.6 million in the same period of 2025. This growth was driven by higher net interest income and a $4.7 million gain on the sale of a limited partnership investment during the nine-month period.
HCW Biologics Inc. reported a significant revenue increase to $6.7 million for the nine months ended September 30, 2026, primarily driven by a $3.5 million noncash licensing agreement. Despite this, the company recorded a net loss of $5.0 million for the period and an accumulated deficit of $113.5 million, reflecting ongoing research and development costs and substantial equity dividends to investors.
RenX Enterprises reported record Q3 2026 revenue of $4.48 million, representing 27.5% year-over-year growth and its third consecutive quarter of sequential growth. The company achieved a record gross margin of 34.3% and completed construction of its Microtec mill, with production expected to begin in January 2027.
Term
Q3 2026
“RenX grew revenue every quarter of 2026, expanded gross margin to its best level of the year, and delivered a third straight profitable quarter in Logistics. That is fundamental growth, quarter after quarter, generated by operations.”
David Villarreal, Chief Executive Officer of RenX Enterprises Corp.
Perspective Therapeutics Director Robert F. Williamson III Buys $15.6K of Stock
Robert F. Williamson III, Director, bought 18,609 shares of Perspective Therapeutics, Inc. at $0.84 a share, worth $15.6K in total on Nov 12, 2026. Shares held after the trade: 28,473 (+188.7%).
Perspective Therapeutics Director Frank Morich Buys $15K of Stock
Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.
Perspective Therapeutics Director Lori A. Woods Buys $20K of Stock
Lori A. Woods, Director, bought 23,750 shares of Perspective Therapeutics, Inc. at $0.8438 a share, worth $20K in total on Nov 12, 2026. Shares held after the trade: 28,557 (+494.1%).
HeartCore Enterprises reported Q3 2026 financial results, showing a significant revenue decline to $0.16 million from $1.2 million year-over-year due to fewer successful client IPOs. The company completed its strategic exit from software development services by divesting its interest in HeartCore Luvina to focus on its Go IPO consulting and capital markets advisory business.
Term
Q3 2026
“With the transfer of our interest in HeartCore Luvina completed during the third quarter, we have concluded the portfolio optimization we began earlier this year. HeartCore now operates as a focused Go IPO consulting, capital markets advisory, and financial services company, which we believe allows us to direct management attention and capital toward the areas where we see the greatest long-term opportunity.”
Sumitaka Kanno, HeartCore CEO
“The Nasdaq listing environment remains selective, and a number of our clients have extended their IPO timelines as they work to satisfy stricter exchange and regulatory requirements. We continue to prioritize clients that we believe demonstrate stronger fundamentals, organizational readiness, and a clear path to a U.S. listing, and we are cautiously optimistic that this disciplined approach will support a higher-quality pipeline over time.”
PureCycle Technologies Executive Chairman Fernando Musa Buys $98.5K of Stock
Fernando Musa, Executive Chairman, bought 57,600 shares of PureCycle Technologies, Inc. at $1.71 a share, worth $98.5K in total on Nov 13, 2026. Shares held after the trade: 386,957 (+17.5%).
Powerfleet, Inc. elected Eddie Capel and John Strosahl to its Board of Directors as independent directors, effective November 16, 2026. Both appointees bring extensive enterprise software and SaaS leadership experience, having previously served as CEOs of Manhattan Associates and Jamf, respectively. The appointments are part of the company's strategy to scale its AIoT software-as-a-service platform.
Blaine Browers has resigned as Chief Financial Officer of Cadre Holdings, effective December 31, 2026, to pursue other opportunities. The company has appointed Chad Appleby, the current Vice President & Treasurer, to serve as interim CFO starting January 1, 2027, while a permanent successor is sought.
WidePoint Corporation reported financial results for the third quarter ended September 30, 2026, and provided an update on its DHS CWMS 3.0 contract status. Despite a GAO protest setback, the company was awarded 40 new and replacement task orders valued at $33.7 million during the quarter under existing bridge contracts.
Term
Q3 2026
“I want to acknowledge that the last few months have presented challenges and outcomes that fell short of what we had envisioned for our DHS program. As you know, the Government Accountability Office, or the GAO's decision to sustain the protest filed regarding the pending CWMS 3.0 award, while not unprecedented, was still an unexpected setback.”
Jin Kang, Chief Executive Officer, President and Director
“While delays and setbacks are frustrating, we are well-positioned to withstand near-term headwinds as we await a decision from DHS.”
Jin Kang, Chief Executive Officer, President and Director
Dynex Capital Co-CEO & Chairman of the Board Byron L. Boston Buys $50K of Stock
Byron L. Boston, Co-CEO & Chairman of the Board, bought 4,965 shares of Dynex Capital Inc at $10.07 a share, worth $50K in total on Nov 13, 2026. Shares held after the trade: 897,712 (+0.6%).
Everforth Inc announced a private offering of $500 million in aggregate principal amount of unsecured senior notes due 2031. The company intends to use the net proceeds, along with revolving credit facility borrowings, to redeem its outstanding 4.625% Senior Notes due 2028 and pay related fees.
TriSalus Life Sciences Insider Mats Wahlstrom Buys $112K of Stock
Mats Wahlstrom bought 50,000 shares of TriSalus Life Sciences, Inc. at $2.24 a share, worth $112K in total on Nov 12, 2026. Shares held after the trade: 197,555 (+33.9%).
Dynex Capital Co-CEO and President Smriti Laxman Popenoe Buys $25.7K of Stock
Smriti Laxman Popenoe, Co-CEO and President, bought 2,600 shares of Dynex Capital Inc at $9.90 a share, worth $25.7K in total on Nov 13, 2026. Shares held after the trade: 543,698 (+0.5%).
ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.
US Alliance Corp reported a net loss of $820,543 for the nine months ended September 30, 2026, compared to a loss of $795,892 in the prior year period. Total assets remained stable at $149.4 million, while the company saw a significant shift in its investment portfolio toward mortgage loans and a decrease in cash and cash equivalents.
Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.
Virtuix Holdings reported Q2 fiscal 2027 financial results featuring 55% sequential revenue growth to $1.2 million, driven by a 105% increase in Omni One revenue following its launch for Meta Quest. The company also announced a non-binding letter of intent to acquire defense technology firm STS International for approximately $12 million to expand its presence in the government and defense sectors.
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.
ACNB Corporation has furnished a formal investor presentation deck for the third quarter of 2026. The presentation provides strategic highlights and financial data for the company and its subsidiaries, ACNB Bank and ACNB Insurance Services, to be used in meetings with investors and analysts.
Tancheng Group Co., Ltd. reported zero revenue for the nine months ended September 30, 2026, as it pivoted from product sales to the development of a cultural tourism project. The company recorded a net loss of $338,896 for the period and maintains a significant accumulated deficit of $2.4 million, raising concerns about its ability to continue as a going concern.
Dawson Geophysical reported third quarter 2026 financial results, including fee revenue of $10.8 million and a net loss of $5.2 million. The company noted that two large channel crew jobs were delayed from Q3 into Q4 due to government permitting issues, but highlighted a strengthened backlog and renewed demand for seismic data acquisition in North America.
“Although our financial performance fell short of our expectations in the third quarter, I cannot be more excited about how this Company is positioned to capitalize on the renewed demand for seismic data acquisition services in North America. We are observing increased demand in Canada and in the United States across the oil and gas space and in other non-traditional markets, such as Carbon Capture, Utilization, and Storage (“CCUS”) and geothermal, and we are scheduled to start our first geothermal data acquisition in November.”
Tony Clark, Dawson’s President and CEO
“I evaluate the Company’s performance over the long term rather than quarterly, and 2026 will be the third year in a row of increasing top-line revenue, improved gross margins and higher Adjusted EBITDA, and I expect that to continue in 2027.”
Idaho Strategic Resources reported a significant increase in nine-month revenue to $37.1 million in 2026, up from $27.8 million in 2025, driven by product sales. Net income attributable to the company rose to $12.7 million for the nine-month period, while the company transitioned its investment strategy by transferring $64.2 million of US treasury notes from held-to-maturity to available-for-sale.